Mark Schoenberg Sells 5,222 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 5,222 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the completion of the transaction, the insider owned 139,763 shares in the company, valued at $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Urogen Pharma Price Performance

Shares of URGN stock opened at $28.00 on Thursday. The company has a market capitalization of $1.36 billion, a P/E ratio of -10.18 and a beta of 1.59. The company’s 50-day simple moving average is $25.28 and its two-hundred day simple moving average is $22.79. Urogen Pharma has a one year low of $6.92 and a one year high of $32.37.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. On average, research analysts expect that Urogen Pharma will post -0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on URGN. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. D. Boral Capital reiterated a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Urogen Pharma in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $36.67.

Hedge Funds Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of URGN. Glenmede Trust Co. NA acquired a new stake in Urogen Pharma in the first quarter valued at approximately $189,000. Janus Henderson Group PLC acquired a new stake in Urogen Pharma in the first quarter valued at approximately $343,000. Ally Bridge Group NY LLC acquired a new stake in Urogen Pharma in the first quarter valued at approximately $3,634,000. ADAR1 Capital Management LLC boosted its stake in Urogen Pharma by 139.1% in the first quarter. ADAR1 Capital Management LLC now owns 395,459 shares of the company’s stock valued at $7,110,000 after acquiring an additional 230,084 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in Urogen Pharma by 1,605.5% in the first quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock valued at $697,000 after acquiring an additional 36,478 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.